A new series of isoxazole tethered quinone-amino acid hybrids has been designed and synthesized involving 1,3-dipolar cycloaddition reaction followed by an oxidation reaction using cerium ammonium nitrate (CAN). Using this method, for the first time various isoxazole tethered quinone-phenyl alanine and quinone-alanine hybrids were synthesized from simple commercially available 4-bromobenzyl bromide, propargyl bromide, and 2,5-dimethoxybenzaldehyde in good yield. 1. Introduction Compounds containing the quinone group present an important class of biologically active molecules that are widespread in nature [1–3]. The discoveries of antibiotic [4, 5] and antitumor [6] properties assigned to several natural quinones have raised interest among scientists for use as pharmaceuticals. While antibiotics display an enormous diversity in chemical structures, quinone antibiotics such as Adriamycin, Mitomycin C, and Streptonigrin deserve special attention [7–10]. In this context, search of new molecules containing quinone moiety has always fascinated the organic as well as medicinal chemist. Isoxazole derivatives are an important class of heterocyclic pharmaceuticals and bioactive natural products because of their significant and wide spectrum of biological activities, including potent and selective antagonism of the NMDA receptor and anti-HIV activity. [11, 12]. It shows antihyperglycemic [13], analgesic [14], anti-inflammatory [15], antifungal [16], and antibacterial activity [17]. 3,5-Disubstituted isoxazole derivatives which are biological active include muscimol, dihydromuscimol, micafungin, and cycloserine [18, 19]. Unnatural amino acids, the nonproteinogenic α-amino acids that occur either naturally or chemically synthesized, have been used widely as chiral building block. They have been also used as molecular scaffolds in constructing combinatorial libraries [20]. They represent a powerful tool in drug discovery when incorporated into therapeutic peptidomimetics and peptide analogs [21]. The seminal work on the synthesis of unnatural amino acids has been done by O’Donnell and Maruoka independently, which accelerated the application of this class of amino acid for practical applications [22, 23]. Synthesis of hybrid natural products has gained momentum in recent years [24–26]. It is expected that combining features of more than one biologically active natural segment in a single molecule may result in pronounced pharmacological activity while retaining high diversity and biological relevance. There are a few reports describing the preparation of
References
[1]
P. M. Dewick, Medicinal Natural Products, Chichester, UK, Wiley, 2nd edition, 2002.
[2]
Y. Kimura, “New anticancer agents: In vitro and in vivo evaluation of the antitumor and antimetastatic actions of various compounds isolated from medicinal plants,” In Vivo, vol. 19, no. 1, pp. 37–60, 2005.
[3]
B. Nowicka and J. Kruk, “Occurrence, biosynthesis and function of isoprenoid quinones,” Biochimica et Biophysica Acta, vol. 1797, no. 9, pp. 1587–1605, 2010.
[4]
Z. S. Saify, N. Mushtaq, F. Noor, S. Takween, and M. Arif, “Role of quinone moiety as antitumour agtents: a review,” Pakistan Journal of Pharmaceutical Sciences, vol. 12, no. 2, pp. 21–31, 1999.
[5]
D. R. A. Mans, J. Retel, J. M. S. van Maanen et al., “Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded ΦX174 DNA,” British Journal of Cancer, vol. 62, no. 1, pp. 54–60, 1990.
[6]
K. Ishiguro, K. Takahashi, K. Yazawa, S. Sakiyama, and T. Arai, “Binding of saframycin A, a heterocyclic quinone anti-tumor antibiotic to DNA as revealed by the use of the antibiotic labeled with [14C]tyrosine or [14C]cyanide,” The Journal of Biological Chemistry, vol. 256, no. 5, pp. 2162–2167, 1981.
[7]
D. L. Boger, M. Yasuda, L. A. Mitscher, S. D. Drake, P. A. Kitos, and S. C. Thompson, “Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones,” Journal of Medicinal Chemistry, vol. 30, no. 10, pp. 1918–1928, 1987.
[8]
W. J. Pigram, W. Fuller, and L. D. Hamilton, “Stereochemistry of intercalation: interaction of daunomycin with DNA,” Nature: New Biology, vol. 235, no. 7, pp. 17–19, 1972.
[9]
V. N. Iyer and W. Szybalski, “Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA,” Science, vol. 145, no. 3627, pp. 55–58, 1964.
[10]
R. Cone, S. K. Hasan, J. W. Lown, and A. R. Morgan, “The mechanism of the degradation of DNA by streptonigrin,” Canadian Journal of Biochemistry, vol. 54, no. 3, pp. 219–223, 1976.
[11]
P. Conti, M. de Amici, G. Grazioso et al., “Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids,” Journal of Medicinal Chemistry, vol. 48, no. 20, pp. 6315–6325, 2005.
[12]
S. Srivastava, L. K. Bajpai, S. Batra et al., “In search of new chemical entities with spermicidal and anti-HIV activities,” Bioorganic and Medicinal Chemistry, vol. 7, no. 11, pp. 2607–2613, 1999.
[13]
A. Kumar, R. A. Maurya, S. Sharma et al., “Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents,” Bioorganic and Medicinal Chemistry, vol. 17, no. 14, pp. 5285–5292, 2009.
[14]
T. Karabasanagouda, A. V. Adhikari, and M. Girisha, “Synthesis of some new pyrazolines and isoxazoles carrying 4-methylthiophenyl moiety as potential analgesic and antiinflammatory agents,” Indian Journal of Chemistry—Section B Organic and Medicinal Chemistry, vol. 48, no. 3, pp. 430–437, 2009.
[15]
B. R. Dravyakar, D. P. Kawade, P. B. Khedekar, and K. P. Bhusari, “Design and syntheses of some new diphenylaminoisoxazolines as potent anti-inflammatory agent,” Indian Journal of Chemistry B: Organic and Medicinal Chemistry, vol. 47, no. 10, pp. 1559–1567, 2008.
[16]
S. B. Jadhav, R. A. Shastri, K. V. Gaikwad, and S. V. Gaikwad, “Synthesis and antimicrobial studies of some novel pyrazoline and isoxazoline derivatives,” E-Journal of Chemistry, vol. 6, supplement 1, pp. S183–S188, 2009.
[17]
J. J. Talley, D. L. Brown, J. S. Carter et al., “4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2,” Journal of Medicinal Chemistry, vol. 43, no. 5, pp. 775–777, 2000.
[18]
T. M. V. D. Pinho e Melo, “Recent advances on the synthesis and reactivity of isoxazoles,” Current Organic Chemistry, vol. 9, no. 10, pp. 925–958, 2005.
[19]
A. R. Katritzky, M. A. C. Button, and S. N. Denisenko, “Efficient synthesis of 3,5-functionalized isoxazoles and isoxazolines via 1,3-dipolar cycloaddition reactions of 1-propargyl- and 1-allylbenzotriazoles,” Journal of Heterocyclic Chemistry, vol. 37, no. 6, pp. 1505–1510, 2000.
[20]
S. Kotha, “The building block approach to unusual α-amino acid derivatives and peptides,” Accounts of Chemical Research, vol. 36, no. 5, pp. 342–351, 2003.
[21]
D. A. Dougherty, “Unnatural amino acids as probes of protein structure and function,” Current Opinion in Chemical Biology, vol. 4, no. 6, pp. 645–652, 2000.
[22]
M. J. O'Donnell, “The preparation of optically active α-amino acids from the benzophenone imines of glycine derivatives,” Aldrichimica Acta, vol. 34, no. 1, pp. 3–15, 2001.
[23]
T. Hashimoto and K. Maruoka, “Recent development and application of chiral phase-transfer catalysts,” Chemical Reviews, vol. 107, no. 12, pp. 5656–5682, 2007.
[24]
L. F. Tietze, H. P. Bell, and S. Chandrasekhar, “Natural product hybrids as new leads for drug discovery,” Angewandte Chemie, vol. 42, no. 34, pp. 3996–4028, 2003.
[25]
G. Mehta and V. Singh, “Hybrid systems through natural product leads: an approach towards new molecular entities,” Chemical Society Reviews, vol. 31, no. 6, pp. 324–334, 2002.
[26]
M. Decker, “Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond,” Current Medicinal Chemistry, vol. 18, no. 10, pp. 1464–1475, 2011.
[27]
S. Kotha, K. Mandal, S. Banerjee, and S. M. Mobin, “Synthesis of novel quinone-amino acid hybrids via cross-enyne metathesis and Diels-Alder reaction as key steps,” European Journal of Organic Chemistry, no. 8, pp. 1244–1255, 2007.
[28]
K. P. Kaliappan and V. Ravikumar, “Design and synthesis of novel sugar-oxasteroid-quinone hybrids,” Organic and Biomolecular Chemistry, vol. 3, no. 5, pp. 848–851, 2005.
[29]
S. Hoppen, U. Emde, T. Friedrich, L. Grubert, and U. Koert, “Natural product hybrids: design, synthesis and biological evaluation of quinone-annonaceous acetogenins,” Angewandte Chemie International Edition in English, vol. 39, no. 12, pp. 2099–2102, 2000.
[30]
G. Mehta and S. S. Ramesh, “Polycyclitols ？ Novel conduritol and carbasugar hybrids as new glycosidase inhibitors,” Canadian Journal of Chemistry, vol. 83, no. 6-7, pp. 581–594, 2005.
[31]
P. R. Kumar, M. Behera, K. Raghavulu, A. J. Shree, and S. Yennam, “Synthesis of novel isoxazole-benzoquinone hybrids via 1,3-dipolar cycloaddition reaction as key step,” Tetrahedron Letters, vol. 53, no. 32, pp. 4108–4113, 2012.
[32]
D. J. Burkhart, B. Twamley, and N. R. Natale, “A new direct synthesis of ACPA and novel AMPA analogues,” Tetrahedron Letters, vol. 42, no. 48, pp. 8415–8418, 2001.
[33]
D. Schulz, P. Beese, B. Ohlendorf et al., “Abenquines A-D: aminoquinone derivatives produced by Streptomyces sp. strain DB634,” Journal of Antibiotics, vol. 64, no. 12, pp. 763–768, 2011.
[34]
J. Sakaki, T. Murata, Y. Yuumoto et al., “Discovery of IRL 3461: a novel and potent endothelin antagonist with balanced ETA/ETB affinity,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 16, pp. 2241–2246, 1998.
[35]
A. R. Katritzky, L. Huang, and R. Sakhuja, “Efficient syntheses of naphthoquinone-dipeptides,” Synthesis, no. 12, Article ID M06709SS, pp. 2011–2016, 2010.
[36]
O. Moriya, H. Takenaka, M. Iyoda, Y. Urata, and T. Endo, “Generation of nitrite oxides via O-tributylstannyl aldoximes, application to the synthesis of isoxazolines and isoxazoles,” Journal of the Chemical Society Perkin Transactions I, no. 4, pp. 413–417, 1994.
[37]
F. Himo, T. Lovell, R. Hilgraf et al., “Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates,” Journal of the American Chemical Society, vol. 127, no. 1, pp. 210–216, 2005.
[38]
S. Minakata, S. Okumura, T. Nagamachi, and Y. Takeda, “Generation of nitrile oxides from oximes using t -BuOI and their cycloaddition,” Organic Letters, vol. 13, no. 11, pp. 2966–2969, 2011.
[39]
R. D. Jadhav, H. D. Mistry, H. Motiwala et al., “A facile one-pot synthesis of 3,5-disubstituted isoxazole derivatives using hydroxy (tosyloxy) iodobenzene,” Journal of Heterocyclic Chemistry, vol. 50, no. 4, pp. 774–780, 2013.
[40]
A. Dondoni, P. P. Giovannini, and A. Massi, “Assembling heterocycle-tethered C-glycosyl and α-amino acid residues via 1,3-dipolar cycloaddition reactions,” Organic Letters, vol. 6, no. 17, pp. 2929–2932, 2004.
[41]
S. Bhosale, S. Kurhade, U. V. Prasad, V. P. Palle, and D. Bhuniya, “Efficient synthesis of isoxazoles and isoxazolines from aldoximes using Magtrieve CrO2,” Tetrahedron Letters, vol. 50, no. 27, pp. 3948–3951, 2009.
[42]
R. Huisgen, “1,3-Dipolar cycloaddition. Past and future,” Angewandte Chemie International Edition, vol. 2, no. 10, pp. 565–568, 1963.
[43]
S. Kanemasa and O. Tsuge, “Recent advances in synthetic applications of nitrile oxide cycloaddition (1981–1989),” Heterocycles, vol. 30, no. 1, pp. 719–736, 1990.
[44]
L. M. Stanley and M. P. Sibi, “Enantioselective copper-catalyzed 1,3-dipolar cycloadditions,” Chemical Reviews, vol. 108, no. 8, pp. 2887–2902, 2008.
[45]
R. Sustmann, “Rolf Huisgen's contribution to organic chemistry, emphasizing 1,3-dipolar cycloadditions,” Heterocycles, vol. 40, no. 1, pp. 1–18, 1995.
[46]
M. J. O'Donnell, K. Wojciechowski, L. Ghosez, M. Navarro, F. Sainte, and J. P. Antoine, “Alkylation of protected a-amino acid derivatives in the presence of potassium carbonate,” Synthesis, no. 4, pp. 313–315, 1984.
[47]
M. J. O'Donnell, W. D. Bennett, and S. Wu, “The stereoselective synthesis of α-amino acids by phase-transfer catalysis,” Journal of the American Chemical Society, vol. 111, no. 6, pp. 2353–2355, 1989.
[48]
M. J. O'Donnell, F. Delgado, and R. S. Pottorf, “Enantioselective solid-phase synthesis of α-amino acid derivatives,” Tetrahedron, vol. 55, no. 20, pp. 6347–6362, 1999.
[49]
B. M. Hoey, J. Butler, and A. J. Swallow, “Reductive activation of mitomycin C,” Biochemistry, vol. 27, no. 7, pp. 2608–2614, 1988.
[50]
P. Nun, V. Pérez, M. Calmès, J. Martinez, and F. Lamaty, “Preparation of chiral amino esters by asymmetric phase-transfer catalyzed alkylations of schiff bases in a ball mill,” Chemistry—A European Journal, vol. 18, no. 12, pp. 3773–3779, 2012.
